5 results
To evaluate the differences in ankle power during push-off and energy cost between prosthetic feet during level, ascending and descending walking.
Primary: To evaluate the efficacy of FF/UMEC/VI to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Secondary: Long term safety and other efficacy parameters.
Primary:To compare the effect of UMEC/VI (62.5/25 mcg once daily) with UMEC (62.5 mcg once daily) on lung functionSecondary:To compare UMEC/VI, UMEC with salmeterol (50 mcg twice daily) on patient reported outcomes and on other COPD efficacy…
Efficacy and safety.
Compare neurophysiological biomarkers with symptom control and stimulation parameters to improve stimulation settings for individual patients with Parkinson*s disease, tremor syndromes and dystonia.